What happened with CLPT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
ClearPoint Neuro helps clinicians guide instruments and deliver treatments to targeted areas of the brain. Hospitals install its ClearPoint navigation equipment, then buy disposable components for procedures; these repeat purchases, rather than equipment sales, drive its device business. Its IRRAflow system manages fluid inside the skull and follows a similar model: hospitals use a durable control unit and purchase disposable catheters and other supplies for each procedure.
Biologics and drug delivery is its largest revenue line. Pharmaceutical and biotechnology customers pay ClearPoint for research and clinical-trial support and buy devices such as the SmartFlow Neuro cannula to deliver therapies into the brain. Preclinical development services provide a significant part of revenue. PTC Therapeutics is an important customer, paying for products and support under a supply agreement that includes minimum quarterly payments.
The business depends on hospitals using the systems for more procedures and drug-development partners continuing their programs. A small group of hospitals supplies a substantial share of system-product revenue, and many components and consumables come from single-source suppliers. Hospital adoption also depends on reimbursement for the procedures. ClearPoint cannot sell or promote new products in the United States before the required authorization; broader drug-delivery uses depend on applicable device authorizations and customers’ therapy approvals.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
ClearPoint depends on brain-delivery partners advancing toward clinical and commercial success and on CLS as Prism’s exclusive manufacturer, while private rivals Monteris Medical and Brainlab shape its competitive market.
uniQure’s investigational Huntington’s gene therapy AMT-130 uses ClearPoint’s technology to deliver treatment into the brain, tying the program’s progress to ClearPoint’s brain-delivery opportunity.
PTC Therapeutics pays ClearPoint for brain-delivery products and support services; PTC and its affiliates supplied approximately 15% of ClearPoint’s biologics and drug-delivery revenue in 2025. The rare-disease drug company’s purchases and minimum quarterly payments matter directly to that revenue stream.
NeuroOne competes with ClearPoint’s Prism laser therapy through OneRF, which destroys targeted brain tissue, and is developing products to deliver drugs into brain tissue under pressure, competing with ClearPoint’s convection-enhanced delivery systems. Watch OneRF’s commercialization through its exclusive distributor Zimmer and progress in drug-delivery development.
Medtronic gives healthcare providers alternatives to ClearPoint in MRI-guided laser treatment, precise placement of instruments in the brain, and intracranial fluid drainage and pressure monitoring. Its new products in these areas matter to competition facing ClearPoint’s Prism, navigation and IRRAflow offerings.
Integra LifeSciences competes with ClearPoint in systems that precisely position instruments for brain surgery and with IRRAflow in intracranial drainage and monitoring. Its Codman Specialty Surgical business sells neurosurgery products, making its pressure-monitoring and hydrocephalus-management offerings the relevant products to watch.
Zimmer Biomet’s ROSA brain robot offers surgical teams an operating-room alternative to ClearPoint’s systems for precisely positioning instruments in the brain. ROSA is the product to watch as ClearPoint expands navigation beyond MRI-guided procedures into full operating-room workflows.
Integra LifeSciences Holdings earningsIART
Integra LifeSciences’ report will show demand for brain-surgery positioning and intracranial drainage products that compete with ClearPoint Neuro’s navigation systems and IRRAflow in overlapping hospital workflows.
Look for sales or demand signals in Integra’s neurosurgery products for brain-surgery positioning, pressure monitoring and hydrocephalus management. Strong demand would show hospitals are still buying for workflows that overlap with ClearPoint Neuro’s, keeping competition for adoption firm; weaker demand could make the market less demanding, but would not prove ClearPoint Neuro is gaining orders. The takeaway is the strength of hospital demand for these products, not ClearPoint Neuro’s own results.
ClearPoint Neuro, Inc. earningsThis company
ClearPoint Neuro sells neurosurgery devices and disposables and supports brain-delivery programs, so this report will show whether both revenue streams are growing.
Read biologics and drug-delivery revenue alongside neurosurgery navigation and therapy revenue, and check whether equipment and software sales also contribute. Growth in both product sales and services would point to demand from hospital procedures as well as drug-development programs; growth driven mainly by services or a few hospital and drug-company programs would leave the revenue base narrow. If revenue weakens while cash use remains high, funding pressure also becomes harder to ease. The conclusion is whether growth comes from several parts of the business or rests on a few programs.
Fed Interest Rate Decision
ClearPoint Neuro’s Fed-linked policy rate affects the interest it pays on its $50.9 million of notes, whose rate is tied to Term SOFR, so changes in rates can alter its borrowing costs.
Expected4.0%Last release4.0%
If it comes in above expectations
If policy rates rise more than expected, ClearPoint Neuro may face higher interest costs on its notes as rates feed through to Term SOFR, although the contractual floor and cap limit the effect.
If it comes in below expectations
If policy rates fall below expectations, lower Term SOFR may reduce ClearPoint Neuro’s interest costs on its notes, but only to the extent allowed by the contractual floor and cap.
PTC Therapeutics, Inc. earningsPTCT
PTC Therapeutics buys ClearPoint Neuro’s brain-delivery products and services, and its report can offer clues about whether its drug programs still support that demand.
Watch for PTC Therapeutics’ disclosed drug-program progress and spending. Continued programs and investment would support this customer-linked revenue stream for ClearPoint Neuro; delays or cuts could reduce or defer demand for related products and services. ClearPoint Neuro’s agreement with PTC includes minimum quarterly payments, but that does not guarantee program-related demand will hold. The takeaway is whether this important customer’s development activity continues to support the brain-delivery business.
uniQure N.V. earningsQURE
uniQure’s AMT-130 gene therapy uses ClearPoint Neuro technology to deliver treatment into the brain, so its report can show whether the program continues to support this potential opportunity.
Look for uniQure’s disclosures on AMT-130’s clinical or regulatory progress. If the program advances, the potential opportunity to use ClearPoint Neuro’s brain-delivery technology remains in play; delays, unfavorable findings or a stalled program could postpone or narrow it. Progress in one program does not mean ClearPoint Neuro has received new orders or current-period revenue. The takeaway is whether this potential application still has room to advance, not whether it has become revenue.
